CLINOLIPID 20%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLINOLIPID 20% (CLINOLIPID 20%).
CLINOLIPID 20% is an intravenous fat emulsion (IVFE) providing essential fatty acids (linoleic and alpha-linolenic acids) and a source of calories. It acts as a substrate for energy production and incorporation into cell membranes, and it modulates inflammatory responses via its omega-6 (linoleic acid) and omega-3 (alpha-linolenic acid) content.
| Metabolism | CLINOLIPID is metabolized by lipoprotein lipase in the capillary endothelium to free fatty acids and glycerol. Free fatty acids undergo beta-oxidation in the mitochondria for energy production or are re-esterified into triglycerides. The omega-3 and omega-6 fatty acids are incorporated into cell membranes and can be further elongated and desaturated to form eicosanoids. |
| Excretion | Primarily renal: <5% unchanged; metabolites excreted renally. Biliary/fecal: negligible. |
| Half-life | Terminal elimination half-life: approximately 11-13 hours for the lipid emulsion; clinical context: continuous infusion maintains steady-state levels. |
| Protein binding | Not significantly protein-bound (lipids are emulsified); protein binding data not commonly reported. |
| Volume of Distribution | Volume of distribution: approximately 0.1 L/kg (represents plasma volume); clinical meaning: primarily remains in intravascular space. |
| Bioavailability | Intravenous: 100% (only route used). |
| Onset of Action | Intravenous: immediate as a lipid source; clinical effect (caloric provision) begins with infusion start. |
| Duration of Action | Duration: 12-24 hours for metabolic effects; clinical notes: infused over 12-24 hours to meet caloric needs. |
1-2 g/kg/day (10-20 mL/kg/day) intravenously over 12-24 hours, not to exceed 2.5 g/kg/day.
| Dosage form | EMULSION |
| Renal impairment | No dose adjustment required; use caution in severe renal impairment due to potential accumulation of excipients. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated. |
| Pediatric use | 0.5-3 g/kg/day intravenously; start at 0.5-1 g/kg/day and titrate upward as tolerated. |
| Geriatric use | Use lowest effective dose; monitor for fluid overload and hypertriglyceridemia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLINOLIPID 20% (CLINOLIPID 20%).
| Breastfeeding | It is not known whether Clinolipid 20% is excreted in human milk. Many components of lipid emulsions are endogenous substances and are present in breast milk. Caution should be exercised when administered to a nursing woman. No M/P ratio is available. |
| Teratogenic Risk | Clinolipid 20% is a lipid emulsion providing essential fatty acids and calories. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this formulation. Lipid emulsions are generally considered low risk for teratogenicity because they are physiologic substrates. However, use during pregnancy should be limited to situations where clear need is established, especially during the first trimester. No specific fetal risks have been documented. |
■ FDA Black Box Warning
WARNING: DEATH IN PRETERM INFANTS. Death in preterm infants has been reported in association with intravenous administration of lipid emulsions, including CLINOLIPID. Autopsy findings included intravascular fat accumulation in the lungs. Preterm infants have low levels of lipoprotein lipase and may develop hyperlipidemia, leading to fat accumulation in the lungs and death. CLINOLIPID is contraindicated in preterm infants.
| Serious Effects |
["Hypersensitivity to egg, soybean, peanut, or to any component of the formulation; severe hyperlipidemia; severe coagulation disorders; bone marrow aplasia; preterm infants; known allergy to fish or fish products"]
| Precautions | ["Hypersensitivity reactions, including anaphylaxis; risk of fat overload syndrome (hypertriglyceridemia, hepatomegaly, coagulopathy, fever, coma); risk of infections due to lipid emulsion; monitor serum triglycerides, liver function, and coagulation parameters; use caution in patients with severe hepatic or renal impairment, pancreatitis, hyperlipidemia, or sepsis"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum triglycerides, liver function tests, coagulation parameters, and complete blood count. Fetal monitoring should include standard obstetric assessments such as ultrasound for growth and well-being if prolonged use occurs. Monitor for signs of fat overload syndrome (hepatomegaly, splenomegaly, thrombocytopenia, coagulopathy). |
| Fertility Effects | No studies on fertility have been conducted with Clinolipid 20%. There is no expected adverse effect on fertility based on its composition of naturally occurring lipids. However, underlying maternal malnutrition may indirectly affect fertility and pregnancy outcomes. |